ADRX Fail-to-Deliver
ADARx Pharmaceuticals, Inc. (ADRX) operates in the Industrials sector, specifically the Specialty Business Services industry, with a market capitalization near $2.04B, listed on NASDAQ, carrying a beta of 0.00 to the broader market. ADARx Pharmaceuticals, Inc. Led by Zhen Li, public since 2026-09-25.
No records carrying symbol ADRX appear in the SEC's published NSCC CNS fails-to-deliver data for settlement dates August 1, 2026 through September 14, 2026.
Our records hold no fail-to-deliver for ADRX.
Frequently asked ADRX fail-to-deliver questions
- Has ADRX had any fails-to-deliver recently?
- No records carrying symbol ADRX appear in the SEC's published NSCC CNS fails-to-deliver data for settlement dates August 1, 2026 through September 14, 2026. Our records hold no fail-to-deliver for ADRX. The SEC publishes the first half of each month at the month's end and the second half around the 15th of the next month, so this check covers settlement dates through September 14, 2026.
- What does it mean when ADRX is absent from the SEC fails-to-deliver data?
- The SEC's files give the aggregate net balance of shares that failed to be delivered in NSCC's Continuous Net Settlement system, by security and settlement date. Since September 16, 2008 a security has a record for every settlement date on which that balance was above zero, and none when it was zero. This check is by symbol, so a fail reported only under a CUSIP or a former symbol is not counted.
Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.
Learn how fails-to-deliver is reported and how to read the data →